Demonstration of pulmonary mass defect by iodine-123 N,N,N'trimethyl-N'[2-hydroxy-3-methyl-5-iodobenzyl]-1,3-propanediamine lung imaging.
A patient whose huge lung mass was demonstrated as a large defect on I-123 N,N,N'trimethyl-N'[2-hydroxy-3-methyl-5-iodobenzyl]-1,3-propanediamine (HIPDM) lung imaging is presented. I-123 HIPDM, a lipophilic agent, is designed for early detection of abnormal cerebral perfusion. Since up to 50% of the administered agent is accumulated and perhaps metabolized in the lung, the radiopharmaceutical may be potentially useful for detection of pathology of the lung in addition to evaluation of pulmonary amine metabolism.
D000368:Aged; D002283:Carcinoma, Bronchogenic / Q000000981:diagnostic imaging*; D006801:Humans; D007462:Iodobenzenes; D008175:Lung Neoplasms / Q000000981:diagnostic imaging*; D008297:Male; D011877:Radionuclide Imaging
D007462:Iodobenzenes; C036739:N,N,N'-trimethyl-N'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine